“[DCTs] bring research closer to the patient population that we want to serve, and does so in a manner in which it’s simplified, it’s straightforward, and our patients understand what they’re part of and how they’re making a difference.”
— Leigh Burgess, CEO & President, High Road Strategy
Learn how DCTs can improve trial diversity, speed study start-up, and perhaps stem the “one and done” phenomenon for some Principal Investigators.
“When people hear decentralized trials, they hear moving away from the center or moving away from what we’ve always done. When what we mean as an industry is making trials more convenient… more appropriate for patients.”
— Sans Thakur, Chief Growth Officer, Medable
Learn how DCTs can elevate sites and how savvy ones can leverage new tools and technology to improve efficiency.
“More than 70% of the [American] population lives more than two hours away from a research site…The burden is a bigger obstacle for many rural and minority groups because it can be more difficult for them to take time off from work to devote adequate time to a trial. Decreasing that burden should help [close] the disparity.”
— Dr. Pamela Tenaerts, Chief Scientific Officer, Medable
Nearly Half of Surveyed Stakeholders Already Use Remote Monitoring for DCTs
“Forty-four percent of recently surveyed pharmaceutical, biotechnology, and clinical research professionals have already adopted remote patient monitoring for decentralized clinical trials or have plans to within the next 12 months, according to survey results from VivaLNK.”
Two Questions and Five Suggestions Before You Begin Implementing Decentralized Trials
“Identifying the urgent issues to be addressed to increase the likelihood of a successful project starts with thoughtful discussion…and this will only expand our ability to move forward for the betterment of clinical research.”
Looming Changes Could Catch Clinical Trial Professionals Off Guard
“If I were a clinical research coordinator, I’d keep my ear to the ground from a career perspective…while technology and other forces suggest there might be fewer sties needed to perform trials in the coming years, that doesn’t necessarily mean there will be fewer professional opportunities.”
FDA Puts Spotlight on Decentralized Clinical Trials
Decentralized clinical trials offer opportunities to optimize efficiencies in clinical trials, a number of U.S. Food and Drug Administration (FDA) officials, including Dr. Isaac R. Rodriguez-Chavez, have said at recent public conferences.
“Hi ACRP community. I am very interested in chatting with my fellow professionals who have worked with either a home health agency and/or phlebotomy service who has performed study visits in the subject’s home. I’m curious how your experience was and if you’d like to chat with me about it. I am not conducting research just asking my professional colleagues how the DCT are practically being conducted and how they’re going.”